This study was aimed at evaluating the safety and efficacy of a single-dose intravenous infusion of TMS-007 in symptomatic patients with ischemic stroke, including cardioembolic and atherothrombotic stroke and lacuna infarction, who were ineligible for t-PA therapy or endovascular thrombectomy. This evidence concerns the gene PLAT and stroke disorder.